Skip to main content

Advertisement

Table 2 Multivariable Cox proportional hazards regression analysis of factors associated with two-year mortality of Jordanian cancer patients at KHCC who smoke (n = 2384)

From: Smoking cessation care can translate to lower hazard of death in the short-run in cancer patients - a retrospective cohort study to demonstrate the value of smoking cessation services within the treatment phase of cancer

Variable HR (95% CI)
Patient group (with regards to being seen at cessation clinic)
 Smokers who were seen [within a year of diagnosis] more than once at the clinic and whose records indicated abstinence at atleast two follow-up points (group A) Reference group
 Smokers who were seen [within a year of diagnosis] more than once at the clinic and whose records indicated abstinence at only one follow-up point (group B) 1.3 (0.65–2.6)
 Smokers who were seen [within a year of diagnosis] more than once at the clinic and whose records indicated no abstinence at any follow-up point (group C) 2.7 (1.4–5.0)*
 Smokers who were never seen at the clinic or were seen after a year from diagnosis (group D) 2.8 (1.7–4.6)*
Female (versus male) 0.67 (0.53–0.84)*
Marital status
 Married Reference group
 Single 0.88 (0.62–1.2)
 Other 1.1 (0.74–1.6)
Age at diagnosis
 18–30 Reference group
 31–40 1.5 (0.91–2.4)
 41–50 1.6 (0.98–2.6)
 51–60 1.8 (1.1–2.9)*
 61–70 2.1 (1.3–3.5)*
  > 70 2.1 (1.2–3.5)*
Year of diagnosis
 2012 Reference group
 2013 0.83 (0.66–1.0)
 2014 0.84 (0.66–1.1)
 2015 0.89 (0.70–1.1)
 2016 0.72 (0.52–0.99)*
Geographic area
 Central Reference group
 North 1.1 (0.83–1.4)
 South 0.91 (0.65–1.3)
Cancer site (type)
 Solid, tobacco-related: head, neck, respiratory, esophageal (reference group) Reference group
 Solid, tobacco-related, other: cervical, pancreatic, liver, stomach, urinary 0.75 (0.60–0.93)*
 Solid, not tobacco-related 0.92 (0.72–1.2)
 Hematological, tobacco-related 0.76 (0.47–1.2)
 Hematological, not tobacco-related 0.20 (0.14–0.27)*
Stage
 Local (reference group) Reference group
 In-situ 0.37 (0.10–1.6)
 Regional* 3.7 (2.5–5.4)*
 Distant and unstaged 13.1 (9.0–19.1)*
Received chemotherapy (yes/no) 0.49 (0.39–0.61)*
Received surgery (yes/no) 0.39 (0.31–0.50)*
Received radiation (yes/no) 0.73 (0.60–0.87)*
Received immunotherapy (yes/no) 0.81 (0.29–1.3)
Received hormonal therapy (yes/no) 0.18 (0.11–0.28)*
Received bone marrow transplant (yes/no) 0.46 (0.27–0.77)
Having diabetes 1.2 (0.94–1.4)
Having cardio- or cerebrovascular disease 0.99 (0.81–1.2)
Having respiratory disease 1.2 (0.89–1.5)
  1. *p < 0.05